MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 525712 | Name: ML 9 (Free Base)

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ML 9 Free Base is a myosin light chain kinase (MLCK) inhibitor. ML-9 enhances the anticancer activity of docetaxel, suggesting its potential application as an adjuvant to existing anticancer chemotherapy. The complex effect of ML-9 on autophagy and indentified ML-9 as an attractive tool for targeting autophagy in cancer therapy through dual inhibition of both the Akt pathway and the autophagy.

Chemical Structure

ML 9 (Free Base)
ML 9 (Free Base)
CAS#110448-31-2

Theoretical Analysis

MedKoo Cat#: 525712

Name: ML 9 (Free Base)

CAS#: 110448-31-2

Chemical Formula: C15H17ClN2O2S

Exact Mass: 324.0699

Molecular Weight: 324.83

Elemental Analysis: C, 55.46; H, 5.28; Cl, 10.91; N, 8.62; O, 9.85; S, 9.87

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
ML9; ML-9; ML 9
IUPAC/Chemical Name
1-((5-chloronaphthalen-1-yl)sulfonyl)-1,4-diazepane
InChi Key
OZSMSRIUUDGTEP-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H17ClN2O2S/c16-14-6-1-5-13-12(14)4-2-7-15(13)21(19,20)18-10-3-8-17-9-11-18/h1-2,4-7,17H,3,8-11H2
SMILES Code
O=S(N1CCNCCC1)(C2=C3C=CC=C(Cl)C3=CC=C2)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 324.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kondratskyi A, Yassine M, Slomianny C, Kondratska K, Gordienko D, Dewailly E, Lehen'kyi V, Skryma R, Prevarskaya N. Identification of ML-9 as a lysosomotropic agent targeting autophagy and cell death. Cell Death Dis. 2014 Apr 24;5:e1193. doi: 10.1038/cddis.2014.156. PubMed PMID: 24763050; PubMed Central PMCID: PMC4001310. 2: Ito S, Kume H, Honjo H, Kodama I, Katoh H, Hayashi H, Shimokata K. ML-9, a myosin light chain kinase inhibitor, reduces intracellular Ca2+ concentration in guinea pig trachealis. Eur J Pharmacol. 2004 Feb 23;486(3):325-33. PubMed PMID: 14985055. 3: Honjo M, Inatani M, Kido N, Sawamura T, Yue BY, Honda Y, Tanihara H. A myosin light chain kinase inhibitor, ML-9, lowers the intraocular pressure in rabbit eyes. Exp Eye Res. 2002 Aug;75(2):135-42. PubMed PMID: 12137759. 4: Kokubu K, Tani E, Nakano M, Minami N, Shindo H. Effects of ML-9 on experimental delayed cerebral vasospasm. J Neurosurg. 1989 Dec;71(6):916-22. PubMed PMID: 2585084. 5: Shi J, Takahashi S, Jin XH, Li YQ, Ito Y, Mori Y, Inoue R. Myosin light chain kinase-independent inhibition by ML-9 of murine TRPC6 channels expressed in HEK293 cells. Br J Pharmacol. 2007 Sep;152(1):122-31. Epub 2007 Jul 2. PubMed PMID: 17603544; PubMed Central PMCID: PMC1978268. 6: Kishi H, Bao J, Kohama K. Inhibitory effects of ML-9, wortmannin, and Y-27632 on the chemotaxis of vascular smooth muscle cells in response to platelet-derived growth factor-BB. J Biochem. 2000 Nov;128(5):719-22. PubMed PMID: 11056381. 7: Coling DE, Bartolami S, Rhee D, Neelands T. Inhibition of calcium-dependent motility of cochlear outer hair cells by the protein kinase inhibitor, ML-9. Hear Res. 1998 Jan;115(1-2):175-83. PubMed PMID: 9472746. 8: Yamamoto-Yamaguchi Y, Makishima M, Kanatani Y, Kasukabe T, Honma Y. Reversible differentiation of human monoblastic leukemia U937 cells by ML-9, an inhibitor of myosin light chain kinase. Exp Hematol. 1996 May;24(6):682-9. PubMed PMID: 8635523. 9: Barros LF, Marchant RB, Baldwin SA. Dissection of stress-activated glucose transport from insulin-induced glucose transport in mammalian cells using wortmannin and ML-9. Biochem J. 1995 Aug 1;309 ( Pt 3):731-6. PubMed PMID: 7639686; PubMed Central PMCID: PMC1135693. 10: Inoue G, Kuzuya H, Hayashi T, Okamoto M, Yoshimasa Y, Kosaki A, Kono S, Okamoto M, Maeda I, Kubota M, et al. Effects of ML-9 on insulin stimulation of glucose transport in 3T3-L1 adipocytes. J Biol Chem. 1993 Mar 5;268(7):5272-8. PubMed PMID: 7680348. 11: Isemura M, Mita T, Satoh K, Narumi K, Motomiya M. Myosin light chain kinase inhibitors ML-7 and ML-9 inhibit mouse lung carcinoma cell attachment to the fibronectin substratum. Cell Biol Int Rep. 1991 Oct;15(10):965-72. PubMed PMID: 1773444. 12: Nakanishi A, Yoshizumi M, Hamano S, Morita K, Oka M. Myosin light-chain kinase inhibitor, 1-(5-chlornaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine (ML-9), inhibits catecholamine secretion from adrenal chromaffin cells by inhibiting Ca2+ uptake into the cells. Biochem Pharmacol. 1989 Aug 15;38(16):2615-9. PubMed PMID: 2764985. 13: Ito M, Tanabe F, Sato A, Ishida E, Takami Y, Shigeta S. Inhibition of natural killer cell-mediated cytotoxicity by ML-9, a selective inhibitor of myosin light chain kinase. Int J Immunopharmacol. 1989;11(2):185-90. PubMed PMID: 2703279. 14: Ishikawa T, Chijiwa T, Hagiwara M, Mamiya S, Saitoh M, Hidaka H. ML-9 inhibits the vascular contraction via the inhibition of myosin light chain phosphorylation. Mol Pharmacol. 1988 Jun;33(6):598-603. PubMed PMID: 3380076.